BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113 [PMID: 28533919 DOI: 10.4292/wjgpt.v8.i2.103] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Lampič K, Trontelj J, Prosen H, Drobne D, Šmid A, Vovk T. Determination of 6-thioguanine and 6-methylmercaptopurine in dried blood spots using liquid chromatography-tandem mass spectrometry: Method development, validation and clinical application. Clinica Chimica Acta 2019;499:24-33. [DOI: 10.1016/j.cca.2019.08.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, Scherl E, Battat R. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00344-X. [PMID: 33798711 DOI: 10.1016/j.cgh.2021.03.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Magro F, Cordeiro G, Dias AM, Estevinho MM. Inflammatory Bowel Disease - Non-biological treatment. Pharmacol Res 2020;160:105075. [PMID: 32653651 DOI: 10.1016/j.phrs.2020.105075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Nayar S, Cho JH. From single-target to cellular niche targeting in Crohn's disease: intercepting bad communications. EBioMedicine 2021;74:103690. [PMID: 34773892 DOI: 10.1016/j.ebiom.2021.103690] [Reference Citation Analysis]
5 Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. J Gastroenterol Hepatol 2020;35:225-32. [PMID: 31397010 DOI: 10.1111/jgh.14825] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Choi SJ, Kim MS, Kim ES, Lee J, Lee JM, Choi HS, Keum B, Jeen YT, Lee HS, Chun HJ, Kim CD. Higher risk of tuberculosis in combination therapy for inflammatory bowel disease: A nationwide population-based cohort study in South Korea. Medicine (Baltimore) 2020;99:e22897. [PMID: 33126343 DOI: 10.1097/MD.0000000000022897] [Reference Citation Analysis]
7 Yousefi‐ahmadipour A, Rashidian A, Mirzaei MR, Farsinejad A, Pourmohammadi‐nejad F, Ghazi‐khansari M, Ai J, Shirian S, Allahverdi A, Saremi J, Ebrahimi‐barough S. Combination therapy of mesenchymal stromal cells and sulfasalazine attenuates trinitrobenzene sulfonic acid induced colitis in the rat: The S1P pathway. J Cell Physiol 2019;234:11078-91. [DOI: 10.1002/jcp.27944] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Iborra M, Herreras J, Boscá-Watts MM, Cortés X, Trejo G, Cerrillo E, Hervás D, Mínguez M, Beltrán B, Nos P. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse. Dig Dis Sci 2019;64:1612-21. [PMID: 30604371 DOI: 10.1007/s10620-018-5429-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Vasudevan A, Raghunath A, Anthony S, Scanlon C, Sparrow MP, Gibson PR, van Langenberg DR. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease. Dig Dis Sci 2019;64:1622-31. [PMID: 30560332 DOI: 10.1007/s10620-018-5422-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Jacobsen LM, Newby BN, Perry DJ, Posgai AL, Haller MJ, Brusko TM. Immune Mechanisms and Pathways Targeted in Type 1 Diabetes. Curr Diab Rep 2018;18:90. [PMID: 30168021 DOI: 10.1007/s11892-018-1066-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
11 Cock IE. Is the pharmaceutical industry's preoccupation with the monotherapy drug model stifling the development of effective new drug therapies? Inflammopharmacology 2018;26:861-79. [PMID: 29736688 DOI: 10.1007/s10787-018-0488-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Haider M, Lashner B. Dual Targeted Therapy for the Management of Inflammatory Bowel Disease. J Clin Gastroenterol 2021;55:661-6. [PMID: 34238847 DOI: 10.1097/MCG.0000000000001583] [Reference Citation Analysis]